Radiopharm Theranostics Limited American Depositary Shares (RADX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has a cash flow conversion efficiency ratio of -0.168x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.74 Million) by net assets ($52.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Radiopharm Theranostics Limited American to measure how many days the company can operate on defensive assets alone.
Radiopharm Theranostics Limited American Depositary Shares - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Big Digital Energy, Inc.
NASDAQ:BGDE
|
1.112x |
|
Aberdeen Global IF Inc
NYSE MKT:FCO
|
0.021x |
|
Accentis
BR:ACCB
|
0.043x |
|
Chumpower Machinery Corp
TWO:4575
|
0.030x |
|
Remsons Industries Limited
NSE:REMSONSIND
|
0.250x |
|
Genus Paper & Boards Limited
NSE:GENUSPAPER
|
0.034x |
|
Hae In
KO:003010
|
0.201x |
|
Horizon Space Acquisition II Corp. Ordinary share
NASDAQ:HSPT
|
-1.741x |
Annual Cash Flow Conversion Efficiency for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Radiopharm Theranostics Limited American stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $42.87 Million | $-36.65 Million | -0.855x | -1.76% |
| 2024-06-30 | $27.35 Million | $-22.98 Million | -0.840x | -65.01% |
| 2023-06-30 | $45.58 Million | $-23.20 Million | -0.509x | -223.23% |
| 2022-06-30 | $62.96 Million | $-9.92 Million | -0.157x | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more